Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
作者信息
Qiu Hai-Bo
机构信息
Department of Gastric Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
出版信息
Thorac Cancer. 2020 Dec;11(12):3419-3421. doi: 10.1111/1759-7714.13690. Epub 2020 Oct 12.
Abstract
摘要
相似文献
1
Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.替雷利珠单抗联合化疗用于一线治疗晚期食管鳞状细胞癌和胃/胃食管交界腺癌的安全性和有效性。
Thorac Cancer. 2020 Dec;11(12):3419-3421. doi: 10.1111/1759-7714.13690. Epub 2020 Oct 12.
2
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.替雷利珠单抗联合化疗作为晚期食管鳞癌和胃/胃食管结合部腺癌的一线治疗。
Clin Cancer Res. 2020 Sep 1;26(17):4542-4550. doi: 10.1158/1078-0432.CCR-19-3561. Epub 2020 Jun 19.
3
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.帕博利珠单抗治疗晚期胃及胃食管结合部腺癌。
Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2.
4
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.苏拉非尼联合特泊替尼（一种无化疗方案）治疗晚期胃/胃食管结合部腺癌、食管鳞癌或胆道癌的疗效和安全性。
Cancer Immunol Immunother. 2024 May 7;73(7):119. doi: 10.1007/s00262-024-03677-7.
5
PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811.PD-L1作为帕博利珠单抗在HER2阳性胃或胃食管交界腺癌中的预测生物标志物——关于KEYNOTE-811的评论
Chin Clin Oncol. 2024 Aug;13(4):59. doi: 10.21037/cco-24-28. Epub 2024 Jun 6.
6
Current status of ramucirumab in gastroesophageal adenocarcinoma.雷莫芦单抗在胃食管腺癌中的应用现状。
Future Oncol. 2017 Aug;13(18):1585-1592. doi: 10.2217/fon-2016-0556. Epub 2017 Apr 24.
7
[Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].帕博利珠单抗联合曲妥珠单抗及化疗用于HER2过表达且CPS≥1的晚期或转移性胃或胃食管交界腺癌
Bull Cancer. 2024 Feb;111(2):130-132. doi: 10.1016/j.bulcan.2023.11.004. Epub 2023 Dec 8.
8
Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.替雷利珠单抗联合化疗是晚期胃食管结合部腺癌二线治疗的优选方案。
Anticancer Drugs. 2024 Aug 1;35(7):666-671. doi: 10.1097/CAD.0000000000001607. Epub 2024 Mar 22.
9
[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].新药批准：帕博利珠单抗联合化疗作为晚期/转移性食管癌或HER阴性胃食管腺癌的一线治疗，其PD-L1表达且CPS≥10
Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.
10
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.EORTC-1203-GITCG - “创新”试验：曲妥珠单抗单药与曲妥珠单抗加帕妥珠单抗联合化疗在 HER2 阳性胃和胃食管交界处腺癌围手术期治疗中的疗效对比：EORTC 胃肠道肿瘤研究组、韩国癌症研究组和荷兰上消化道肿瘤组的一项随机 II 期分组试验。
BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.
引用本文的文献
1
Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives.胃癌免疫治疗时代的预测性生物标志物：当前成果与未来展望
Front Immunol. 2025 May 14;16:1599908. doi: 10.3389/fimmu.2025.1599908. eCollection 2025.
2
Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers.与化疗相比，程序性细胞死亡蛋白-1抑制剂联合化疗在上消化道癌治疗中的有效性和耐受性
World J Gastrointest Oncol. 2024 Apr 15;16(4):1613-1625. doi: 10.4251/wjgo.v16.i4.1613.
3
PD-L1 aptamer-functionalized degradable hafnium oxide nanoparticles for near infrared-II diagnostic imaging and radiosensitization.用于近红外二区诊断成像和放射增敏的PD-L1适配体功能化可降解氧化铪纳米颗粒
Front Bioeng Biotechnol. 2023 Jun 7;11:1224339. doi: 10.3389/fbioe.2023.1224339. eCollection 2023.
4
Comparison of McKeown Minimally Invasive Esophagectomy vs sweet esophagectomy for esophageal squamous cell carcinoma: A retrospective study.麦克唐纳微创食管切除术与Sweet食管切除术治疗食管鳞状细胞癌的比较：一项回顾性研究。
Front Oncol. 2022 Dec 19;12:1009315. doi: 10.3389/fonc.2022.1009315. eCollection 2022.
5
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades.从粗放到精准：PD-L1 评估预测 PD-1/PD-L1 阻断治疗的疗效。
Front Immunol. 2022 Aug 3;13:920021. doi: 10.3389/fimmu.2022.920021. eCollection 2022.
本文引用的文献
1
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.替雷利珠单抗联合化疗作为晚期食管鳞癌和胃/胃食管结合部腺癌的一线治疗。
Clin Cancer Res. 2020 Sep 1;26(17):4542-4550. doi: 10.1158/1078-0432.CCR-19-3561. Epub 2020 Jun 19.
2
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.替雷利珠单抗在中国晚期实体瘤患者中的疗效和安全性：一项开放标签、非对照、1/2 期研究。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000437.
3
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
4
The immune landscape of esophageal cancer.食管癌的免疫景观。
Cancer Commun (Lond). 2019 Nov 26;39(1):79. doi: 10.1186/s40880-019-0427-z.
5
National trend of gastric cancer mortality in China (2003-2015): a population-based study.中国胃癌死亡率的全国趋势（2003-2015 年）：一项基于人群的研究。
Cancer Commun (Lond). 2019 May 2;39(1):24. doi: 10.1186/s40880-019-0372-x.
6
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?中国当前癌症形势：2018 年全球癌症统计数据带来的是好消息还是坏消息？
Cancer Commun (Lond). 2019 Apr 29;39(1):22. doi: 10.1186/s40880-019-0368-6.
7
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer.中国临床肿瘤学会（CSCO）：胃癌诊断与治疗临床实践指南。
Cancer Commun (Lond). 2019 Mar 18;39(1):10. doi: 10.1186/s40880-019-0349-9.
8
Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.免疫疗法在晚期胃癌和食管癌治疗中的应用
Anticancer Res. 2018 Oct;38(10):5569-5580. doi: 10.21873/anticanres.12891.
9
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.抗 PD-1 抗体与 FcγRΙ 的结合对其生物学功能有深远影响。
Cancer Immunol Immunother. 2018 Jul;67(7):1079-1090. doi: 10.1007/s00262-018-2160-x. Epub 2018 Apr 23.
10
SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016).SEOM食管癌诊断与治疗临床指南（2016年）
Clin Transl Oncol. 2016 Dec;18(12):1179-1186. doi: 10.1007/s12094-016-1577-y. Epub 2016 Nov 29.
Zotero 插件